Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome

Table 1 Baseline characteristics of patients infected with C. albicans only.

Characteristic	Anidulafungin (n = 74)	Fluconazole (n = 61)	p
Sex, n (%)			0.858
Male	39 (52.7)	34 (55.7)
Female	35 (47.3)	27 (44.3)
Age (years)^a			0.097^b
Mean ± SD	54.6 ± 17.9	59.7 ± 17.1
Range	16-89	24-91
Race or ethnic group, n (%)			0.823
White	59 (79.7)	47 (77.0)
Black	7 (9.5)	8 (13.1)
Other	8 (10.9)	6 (9.8)
Risk factors for Candida infection, n (%)
Central venous catheter	54 (73.0)	47 (77.0)	0.691
Catheter removed within 24 h of study entry	70 (94.6)	56 (91.8)	0.731
Broad-spectrum antibiotics^a	43 (58.1)	44 (72.1)	0.106
Recent surgery	32 (43.2)	29 (47.5)	0.728
Recent hyperalimentation	17 (23.0)	12 (19.7)	0.678
Underlying malignancy	18 (24.3)	18 (29.5)	0.560
Immunosuppressive therapy	11 (14.9)	12 (19.7)	0.497
APACHE II score, n (%)			0.605^b
≤ 20	60 (81.1)	52 (85.2)
> 20	14 (18.9)	9 (14.8)
Mean ± SD (median)	13.7 ± 7.8 (12)	14.3 ± 6.4 (14)
Range	2-37	3-30
Absolute neutrophil count, n (%)^a			0.175
> 500/mm³	73 (98.6)	57 (93.4)
≤ 500/mm³	1 (1.4)	4 (6.6)
Site of infection, n (%)			0.343
Blood only	67 (90.5)	51 (83.6)
Deep tissue infection	7 (9.5)	10 (16.4)

^a Baseline variables significant at the p ≤ 0.20 level.
^b p value calculated using a t-test, assuming continuous distribution of this variable.

ISSN: 1471-2334